In these models, anti-CCL2 antibody treatment, or genetic deletion of CCR2 inhibits the monocyte migration to the tumor-challenged lung and decreases the number of MAMs, which results in the reduction of metastatic tumor burden (43). Here, CCL2 is linked to neoplasm.